Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.
about
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.How Precisely Can Prostate Cancer Be Managed?Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review.A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer.The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancerPrecision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk CalculatorAdverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation.Intraprostatic locations of tumor foci of higher grade missed by diagnostic prostate biopsy among potential candidates for active surveillance.Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria.Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.Obesity and Prostate Cancer: A Focused Update on Active Surveillance, Race, and Molecular Subtyping.Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.Managing localized prostate cancer in the era of prostate-specific antigen screening.PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.Concordance Between Prostate Needle Biopsy and Surgical Histopathology in a Primarily African-American Population.Can nomograms improve our ability to select candidates for active surveillance for prostate cancer?External validation and comparison of two nomograms predicting the probability of Gleason sum upgrading between biopsy and radical prostatectomy pathology in two patient populations: a retrospective cohort study.Clinical and pathologic factors predicting reclassification in active surveillance cohorts.Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.
P2860
Q27308897-5A5B4E83-B8C7-4878-9563-9A780C07C402Q28078942-8E6CD6D6-30CD-4C3F-9DE6-78B5EB4D2133Q30234760-FA2F4C80-D1C9-4E78-8E37-A13172CA6749Q31122903-EAF0035B-6FA8-41AA-B660-20BEB30E1EEAQ36090379-94423D86-3563-4B29-A239-C2F9B929D4E3Q36093723-ACB30A92-F441-4174-A235-E870AF291750Q36201978-AA60FBE3-411C-46EE-9B8B-AF3EA379AE50Q37086267-C6AC481A-E269-46B5-9D27-4E8EB6C2DEE2Q37402603-16D2C48A-3E92-460A-88DA-B0BF202238D8Q37496914-2493AFDD-5ED7-48FC-8F42-43C1A2FD756AQ38588658-803BAD9C-7C9F-417F-9B83-57115321794CQ38846321-11E2DCEA-B23F-40F9-BDA1-594799900558Q38988252-004F3EED-8E54-4417-A8C3-0E5EA3724689Q39356200-9DF95AA3-85B3-46B4-85BB-A67287A2E469Q39387342-1FE0C04B-04FF-4FE3-AD08-59382AB38996Q40463189-F68C7C90-8450-46CA-B0F9-A70A70C645DDQ42770558-2A84A82F-5948-4425-98DD-00CEC3A21BD0Q43089446-AB3C03EA-9837-492F-923C-FBA72497B9FDQ45771110-B52E367B-859B-4BD9-8B23-5262B938B982Q46883564-33618EEE-1E41-4A78-B71D-DB368326977FQ48025252-B1F860B0-FA62-4C6D-9C43-0676E9DD7A83Q49715354-ACC624F9-DDB8-4A70-A8D9-7F3B58215C85Q51609372-4A7BDDC6-043C-4837-A0A4-957D60F2C9B1
P2860
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Development and multi-institut ...... for Gleason 6 prostate cancer.
@en
type
label
Development and multi-institut ...... for Gleason 6 prostate cancer.
@en
prefLabel
Development and multi-institut ...... for Gleason 6 prostate cancer.
@en
P2093
P2860
P356
P1433
P1476
Development and multi-institut ...... for Gleason 6 prostate cancer
@en
P2093
Aria A Razmaria
Chee Paul Lin
David F Jarrard
E Jason Abel
Glen Leverson
Jon A Slezak
Mark S Soloway
Martins Sado
Scott E Eggener
Tracy M Downs
P2860
P304
P356
10.1002/CNCR.28303
P407
P577
2013-09-04T00:00:00Z